Zacks Research Has Bullish Forecast for Omnicell Q4 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research increased their Q4 2024 EPS estimates for Omnicell in a report issued on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Omnicell’s current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

Several other analysts have also recently weighed in on OMCL. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. increased their target price on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Wells Fargo & Company lifted their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Benchmark reiterated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Finally, Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $50.17.

Omnicell Price Performance

OMCL opened at $44.71 on Monday. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -114.64, a PEG ratio of 34.96 and a beta of 0.78. The business has a 50 day simple moving average of $46.17 and a two-hundred day simple moving average of $40.65. Omnicell has a one year low of $25.12 and a one year high of $55.74.

Insider Activity

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OMCL. GAMMA Investing LLC increased its position in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares in the last quarter. 1620 Investment Advisors Inc. increased its holdings in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Omnicell in the second quarter worth $104,000. Summit Global Investments bought a new position in shares of Omnicell during the third quarter valued at $221,000. Finally, QRG Capital Management Inc. purchased a new stake in shares of Omnicell during the third quarter valued at $231,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.